Patterns of recurrence in stage i endometrioid endometrial adenocarcinoma with lymphovascular space invasion

International Journal of Gynecological Cancer

Volumn 23, Issue 1, 2013, Pages 98-104

  Simpkins, Fiona ^a,b   Papadia, Andrea ^b   Kunos, Charles ^c   Michener, Chad ^a   Frasure, Heidi ^c   AbuShahin, Fadi ^a   Mariani, Andrea ^d   Bakkum Gamez, Jamie N ^d   Landrum, Lisa ^e   Moore, Kathleen ^e   Thomas, Sajeena G ^f   Windhorn, Alexandra ^f   Rose, Peter G ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Endometrial cancer; Lymphovascular invasion; Patterns of recurrence

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; ENDOMETRIOID CARCINOMA; ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD VESSELS; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; LYMPHATIC VESSELS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84872287265     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318276d9b6     Document Type: Article

References (27)

1. Siegel R, Desantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220-241.
2. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991;40:55-65.
3. Zaino RJ, Kurman RJ, Diana KL, et al. 15. Pathologic models to predict outcome for women with endometrial adenocarcinoma: the importance of the distinction between surgical stage and clinical stage-a Gynecologic Oncology Group study. Cancer. 1996;77:1115-1121.
4. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744-751.
5. Inoue Y, Obata K, Abe K, et al. The prognostic significance of vascular invasion by endometrial cancer. Cancer. 1996;78:1447-1451.
6. Briët JM, Hollema H, Reesink N, et al. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol. 2005;96:799-804.
7. Cohn DE, Horowitz NS, Mutch DG, et al. Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer? Gynecol Oncol. 2002;87:243-246.
8. Hanson MB, van Nagell JR Jr, Powell DE, et al. The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer. Cancer. 1985;55:1753-1757.
9. Gal D, Recio F, Zamurovic D, et al. Lymphvascular space involvement-a prognostic indicator in endometrial adenocarcinoma. Gynecol Oncol. 1991;42:142-145.
10. Mariani A, Webb MJ, Keeney GL, et al. Predictors of lymphatic failure in endometrial cancer. Gynecol Oncol. 2002;84:437-442.
11. Mariani A, Dowdy SC, Keeney GL, et al. Predictors of vaginal relapse in stage I endometrial cancer. Gynecol Oncol. 2005;97:820-827.
12. Fujimoto T, Nanjyo H, Fukuda J, et al. Endometrioid uterine cancer: histopathologic risk factors of local and distant recurrence. Gynecol Oncol. 2009;112:342-347.
13. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1140-1154.
14. Fisher R. On the interpretation of W2 from contingency tables, and the calculation of P. J R Stat Soc. 1922;85:87-94.
15. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Cox D. Regression models and life tables (with discussion). J R Stat Soc. 1972;34:187-220.
17. Aalders J, Abeler V, Kolstad P, et al. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980;56:419-427.
18. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355:1404-1411.
19. Scholten AN, van Putten WL, Beerman H, et al. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys. 2005;63:834-838.
20. ASTEC/EN.5 Study Group, Blake P, Swart AM, Orton J, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373:137-146.
21. Nout RA, Smith VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high risk (PORTEC-2): an open-label, non inferiority, randomized trial. Lancet. 2010;375:816-823.
22. Creutzberg CL, van Putten WL, Wárlám-Rodenhuis CC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol. 2004;22:1234-1241.
23. Grigsby PW, Perez CA, Kuten A, et al. Clinical stage I endometrial cancer: prognostic factors for local control and distant metastasis and implication of the new FIGO surgical staging system. Int J Oncol Biol Phys. 1992;22:905-911.
24. Rasool N, Nickles Fader A, Seamon L, et al. Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and pattern of recurrence. Gynecol Oncol. 2010;116:10-14.
25. Singh M, Zaino RJ, Filiaci VJ, et al. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2007;106:2159-2166.
26. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22:1234-1241.
27. Hoskins PJ, Swenerton KD, Pike JA, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer a phase II study. J Clin Oncol. 2001;19:4048-4053.